SAGE 250117 32.50P (SAGE250117P32500) Stock Options, News & Quotes

US OptionsDetailed Quotes

SAGE250117P32500

Watchlist

0.00
0.000.00%

15min DelayClose Jan 17 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Trending Stocks as Wall Street Bounces Back With Strong Week
Seeking AlphaJan 18 11:31 ET
Trending Stocks Today | Nukkleus Inches up 3.38% Post-Market
Moomoo NewsJan 17 18:00 ET
Jefferies Initiates Sage Therapeutics(SAGE.US) With Hold Rating, Announces Target Price $8
Moomoo NewsJan 17 13:32 ET · Ratings
Express News | Sage Therapeutics Inc : Jefferies Cuts Target Price to $8 From $9
ReutersJan 17 07:43 ET
Mizuho Securities Maintains Sage Therapeutics(SAGE.US) With Hold Rating
Moomoo NewsJan 15 02:32 ET · Ratings
Sage Therapeutics Seen Shunning Biogen Bid -- Market Talk
WSJJan 14 08:19 ET

Comments

Stock_Drift

Jan 12 17:27

$Sage Therapeutics (SAGE.US)$

Jaguar8

Jan 12 16:02

🟢 Watchlist JANUARY 13, 2025, Monday. NFA. Those with 🟢 are my top picks

NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...

Jaguar8

Jan 10 17:49

ADDED NEWS

$Sage Therapeutics (SAGE.US)$
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
Friday, 10th January at 6:49 pm
No Shareholder Action Required at This Time
Sage Therapeutics, Inc. (NASDAQ: SAGE) ("The Company"), today confirmed that Biogen Inc. (NASDAQ: BIIB) ("Biogen") has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share...

Jaguar8

Jan 10 16:43

NEWS

$Sage Therapeutics (SAGE.US)$
Biogen Inc - Submits Non-Binding Proposal to Buy All Outstanding Shares of Sage Therapeutics' Common Stock Not Owned by Biogen for $7.22/Share in Cash